Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully placed a note loan with a volume of 750 million euros. The note loan was issued with maturity terms of 3, 5, 7 and 10 years and was significantly oversubscribed. “We see such great interest as clear proof of our attractiveness for investors,” said Rainer Lehmann, Chief Financial Officer of Sartorius.
In view of high demand, the targeted minimum volume of 300 million euros was significantly exceeded. Most of the funds will be used for early repayment of the bridge loan that Sartorius had taken out at the end of April in connection with the acquisition of selected life science businesses from Danaher.
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
A new technique allows the design of solid materia...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Han desarrollado un estudio para evaluar la correlación entre el teji...
Portal de biotecnología en España
¡Suscríbase a nuestro newsletter para estar al día con las últimas noticias y ofertas!
2013 © Biotech-Spain.com - Site Developments SL. Todos los derechos reservados. Terminos y Condiciones | Política de Privacidad
Articles
Directory